Core Viewpoint - PepGen Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the effectiveness and safety of its lead product candidate, PGN-EDO51, during a specified period [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired PepGen securities between March 7, 2024, and March 3, 2025 [2][3]. - Investors are reminded of an upcoming deadline to file as lead plaintiff by August 8, 2025, which allows them to represent other class members in the litigation [3]. Group 2: Legal Representation - Bernstein Liebhard LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]. - The firm has a strong track record, having recovered over $3.5 billion for clients since 1993 and has been recognized multiple times for its litigation success [5].

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, inclusive. For more information, submit a form at Sarepta Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb. ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Hims & Hers Health, Inc. (NYSE: HIMS)?Did you purchase your shares between April 29, 2025 and June 22, 2025, inclusive?Did you lose ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive. For more information, submit a form at Hms & Hers Health, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or c ...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Apple Inc. (“Apple” or the “Company”) (NASDAQ: AAPL) between June 10, 2024 and June 9, 2025, inclusive. For more information, submit a form at Apple Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030. ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the safety and clinical trial protocol for its drug RP-A501, which is intended for the treatment of Danon disease [4][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who purchased Rocket securities between February 27, 2025, and May 26, 2025 [4]. - Allegations include that the defendants made false statements about the safety of RP-A501 and failed to disclose serious adverse events, including participant deaths during the clinical trial [5]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file their papers by August 11, 2025, with the understanding that participation as a lead plaintiff is not necessary to share in any potential recovery [6]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [6]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation, being recognized multiple times by The National Law Journal and The Legal 500 [7].

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Organon & Co. ("Organon" or the "Company") (NYSE: OGN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? If you purchased or acquired Organon securities, and/or would like to discuss your leg ...

Group 1 - A complaint has been filed against Vestis Corporation in the United States District Court for the Southern District of New York, alleging violations of the Securities Exchange Act of 1934 [1] - The complaint involves investors who purchased or acquired Vestis securities between May 2, 2024, and May 6, 2025, claiming misrepresentations regarding the company's growth potential [1][3] - Bernstein Liebhard LLP, the law firm representing the investors, has a history of recovering over $3.5 billion for clients and has been recognized for its success in class action litigations [5] Group 2 - Investors interested in participating in the class action must file papers by August 8, 2025, to serve as lead plaintiff, although participation in recovery does not require this role [4] - The representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses unless there is a recovery [4]

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Krispy Kreme, Inc. (“Krispy Kreme” or the “Company”) (NASDAQ: DNUT) between February 25, 2025 and May 7, 2025, inclusive. For more information, submit a form at Krispy Kreme, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or c ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Rocket Pharmaceuticals, Inc. for alleged misrepresentations regarding the safety and clinical trial protocol of its drug RP-A501, which is intended for treating Danon disease [1][3]. Group 1: Lawsuit Details - The lawsuit covers investors who purchased Rocket's securities between February 27, 2025, and May 26, 2025 [1]. - Defendants are accused of failing to disclose serious risks associated with the clinical trial, including Serious Adverse Events (SAEs) and participant deaths [3]. - The company allegedly modified the trial protocol to include a new immunomodulatory agent without informing shareholders [3]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by August 11, 2025 [4]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [4]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions [5].